Off-licence Use of the Angio-Seal™ Arterial Puncture Closure Device  by Bown, M.J. et al.
TECHNICAL NOTE
Off-licence Use of the Angio-SealTM Arterial Puncture
Closure Device
M. J. Bown1, K. S. Blanshard 2, M. L. Cutress1 and R. D. Sayers1
Departments of 1Surgery and 2Radiology, Leicester General Hospital, Leicester, U.K.
Key Words: Angiography; Haemostasis; Angio-SealTM.
Table 1. Sites of `` Off-licence'' Angio-SealTM deployment.
Site Angio-SealTM deployed n
Arterio-venous haemodialysis fistula 6
(PTFE graft) (2)
Peripheral arterial bypass grafts 3
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Arterial puncture for interventional radiological pro-
cedures is associated with infrequent but significant
complications.1,2 The Angio-SealTM device is designed
to provide rapid and secure haemostasis after arterial
puncture and is currently licensed for use in femoral
arterial puncture sites where it has been demonstrated
to be both safe and effective.3,4 However, many angio-
graphic procedures are performed by puncture of
other sites and vessels (autologous and synthetic
grafts, arterio-venous fistulas) and reducing comp-
lications in these groups of patients is probably more
important since they are more likely to have signifi-
cant co-morbidities and any complication is potential-
ly more serious. We describe the off-license use of
the Angio-SealTM device in 12 patients with no
complications.
Patients and Methods
Patients were identified from the audit records of the
Leicester General Hospital radiology department.
This department provides interventional vascular
radiology services for vascular surgery, general sur-
gery, nephrology and renal transplantation. No car-
diac angiography is performed. A retrospective case
note review was performed of all patients who had an
Angio-SealTM device inserted between 25/5/2001Please address all correspondence to: M. Bown, Department of
Surgery, Leicester General Hospital, Gwendolen Road, Leicester,
LE5 4PW, U.K.
1078±5884/02/040372 02 $35.00/0 # 2002 Elsevier Science Ltd. A(when the device was first used in our Hospital) and
26/7/2001. Case-notes were retrieved and those
found to be concerning procedures where the Angio-
SealTM device was used off-licence were reviewed by
one of the authors (MJB).
Results
Out of a total of 86 occasions where the Angio-SealTM
was used during the study period, in 12 cases this was
in situations other than those described as indications
in the product literature (Table 1). It was used on six
occasions in arterio-venous haemodialysis fistulas
(3 brachio-cephalic, 1 brachio-axilliary, and 2 femoro-
femoral PTFE grafts) and 3 times in vascular bypass
grafts (2 autologous vein, 1 PTFE graft).
In one case the Angio-SealTM was placed into the
femoral vein. This was in a patient with the rare con-
dition of afibrinogenaemia. One week prior to the
episode where the Angio-SealTM was used the patient
had developed a significant neck haematoma requir-
ing surgical evacuation after a venous catheter in the
left internal jugular vein had been removed. Venous(PTFE graft) (1)
Femoral artery after failure of
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femoral venous catheter. In order to prevent similar
complications when the femoral venous catheter was
removed, it was exchanged over a guidewire for an
Angio-SealTM with no complications.
Two patients who had undergone diagnostic lower-
limb angiography via a femoral artery puncture devel-
oped significant bleeding following their procedure
despite adequate manual pressure. In these two
patients the original arterial puncture was located
using the Angio-SealTM dilator, re-cannulated and an
Angio-SealTM placed with immediate haemostasis
achieved in both cases.
None of the above patients developed haematoma,
bleeding or distal arterial complications after the
insertion of the Angio-SealTM device.
Discussion
This study demonstrates the versatility of the Angio-
SealTM device in situations for which it was notspecifically designed, such as deployment in veins and
vascular grafts (autologous vein or synthetic). Use in
these situations may enable the treatment of patients
who otherwise would have been denied treatment
due to the high risk of puncture site complications.
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